Previous 10 | Next 10 |
AcelRx Pharmaceuticals Reports Q4 Results, to Acquire Tetraphase Pharmaceuticals AcelRx ( ACRX ) reported its fourth quarter and full-year results while also announcing its plan to acquire Tetraphase Pharmaceuticals (TTPH). The company ended the year with $66.1 million in cash, cash equiva...
Image source: The Motley Fool. AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) Q4 2019 Earnings Call Mar 16, 2020 , 8:30 a.m. ET Operator Continue reading
AcelRx Pharmaceuticals, Inc. (ACRX) Q4 2019 Results Earnings Conference Call March 16, 2020, 08:30 AM ET Company Participants Raffi Asadorian - CFO Vince Angotti - CEO Pamela Palmer - Chief Medical Officer and Co-Founder Koth Cassavaugh - Director of Pharmacy, Auburn Community ...
AcelRx Pharmaceuticals ( ACRX -17.5% ) Q4 results : More news on: AcelRx Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
AcelRx Pharmaceuticals (NASDAQ: ACRX ) has agreed to acquire Tetraphase Pharmaceuticals (NASDAQ: TTPH ) in an all-stock transaction valued at ~$14.4M. Specifically, TTPH stockholders will receive 0.6303 of an ACRX share for each TTPH share owned. More news on: AcelRx Pharmaceuticals, Inc...
AcelRx Pharmaceuticals (NASDAQ: ACRX ) has entered into a definitive merger agreement to acquire Tetraphase Pharmaceuticals (NASDAQ: TTPH ) in a stock for stock deal at an exchange ratio of 0.6303 shares of AcelRx for each Tetraphase share, or ~$14.4M, plus a contingent value right (CVR)...
AcelRx Pharmaceuticals (NASDAQ: ACRX ): Q4 GAAP EPS of -$0.18 in-line. More news on: AcelRx Pharmaceuticals, Inc., Alleghany Corporation, Earnings news and commentary, Healthcare stocks news Read more ...
REDWOOD CITY, Calif. , March 16, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth...
REDWOOD CITY, Calif. , March 16, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the execution of...
REDWOOD CITY, Calif. , March 11, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter and annual financial results before market open on Monday, March 16, 2020 . AcelRx management wi...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...